3.4.21.95	Acetylsalicylic acid	aspirin, reduces markedly platelet aggregating effect induced by VLCII, less effective compared to clopidogrel	2261	
3.4.21.95	ADP	reduces slightly platelet aggregating effect induced by VLCII	13	
3.4.21.95	clopidogrel	P2Y12 adenosine diphosphate (ADP) receptor inhibitor, reduces markedly platelet aggregating effect induced by VLCII	161060	
3.4.21.95	D-Phe-Pro-Arg-chloromethylketone	-	22537	
3.4.21.95	diisopropyl fluorophosphate	-	244	
3.4.21.95	diisopropylfluorophosphate	-	299	
3.4.21.95	heparin	at high concentrations, more than 100 units	227	
3.4.21.95	additional information	no inhibition of the proteolytic activity of VLCII by EDTA and 1,10-phenanthroline, poor inhibition by EGTA. VLCII activity on platelet aggregation is tested after treatment with acetylsalicylic acid (aspirin) irreversible inhibitor of cyclooxygenase-1 (COX-1) and clopidogrel (plavix) antagonist of P2Y12 receptor	2	
3.4.21.95	pefabloc	4-(2-aminoethyl)-benzenesulfonyl fluoride	2236	
3.4.21.95	PMSF	82% inhibition	248	
3.4.21.95	PMSF	-	248